AACR 2024 | KRYSTAL-1: adagrasib with cetuximab in KRAS G12C-mutated CRC

Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from an analysis of the Phase I and II cohorts of the KRYSTAL-1 trial (NCT03785249), which assessed adagrasib with cetuximab in KRAS G12C-mutated colorectal cancer (CRC). Median duration of response, progression-free survival, and overall survival demonstrate clinically meaningful outcomes. Ongoing investigation in the Phase III KRYSTAL-10 trial (NCT04793958) aims to evaluate this combination further as a second-line treatment option for KRASG 12C-mutated CRC. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.